SF3B1 and acute myeloid leukemia: As noted in the U2AF1 section, there is a trial evaluating emavusertib (CA-4948) monotherapy in adults with R/R AML or high-risk MDS with the SF3B1 mutation (NCT04278768), showing a promising early response [157].